Canine cancers represent a tremendous natural resource due to their incidence and striking similarities to human cancers, sharing similar clinical and pathological features as well as oncogenic events including identical somatic mutations. Considering the importance of gene fusions as driver alterations, we explored their relevance in canine cancers. We focused on three distinct human-comparable canine cancers representing different tissues and embryonic origins. Through RNA-Seq, we discovered similar gene fusions as those found in their human counterparts: IGK-CCND3 in B-cell lymphoma, MPB-BRAF in glioma, and COL3A1-PDGFB in dermatofibrosarcoma protuberans-like. We showed not only similar partner genes but also identical breakpoints leading to oncogene overexpression. This study demonstrates similar gene fusion partners and mechanisms in human-dog corresponding tumors and allows for selection of targeted therapies in preclinical and clinical trials with pet dogs prior to human trials, within the framework of personalized medicine.
Introduction
During the last decade, pet dogs have arisen as a relevant but under-used model for cancer genetics and therapies (1) . Although extremely useful for cancer research, rodent models show limitations in their ability to fully reproduce the complexity of spontaneously occurring human tumors (2) . Since canine tumors address part of these concerns, there is a growing interest in using this "natural cancer resource" in translational cancer research for both human and dog medicine benefit. Inclusion of pet dogs in preclinical and clinical trials should accelerate the screening of new treatments by reducing the time and cost of evaluating efficacy, pharmacokinetics and toxicity (3) .
These advantages have already justified ongoing trials with pet dogs (4) .
To use canine cancers as models for the development of new treatments, it is essential to determine human and canine tumors correspondences. The physiopathology of canine tumors presents strong similarities with human tumors in their biological behavior, histopathological features and response to treatments (2) . Moreover, comparative oncology studies show that some canine and human cancers share similar genetic aberrations including chromosomal instability, common cytogenetic aberrations, involvement of identical oncogenes or tumor suppressors, and even identical somatic mutations (5) . The identification of such driver genetic alterations, both in dogs and humans, are highly informative for the development of dedicated new targeted therapies such as the development of c-kit inhibitors for canine mast cell disorders (6) .
Among such driver events, we focused on translocations that generally lead to overexpression of oncogenes. In humans, these recurrent translocations have been described in hematological disorders, sarcomas and carcinomas; most of them are Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 7, 2017; DOI: 10.1158/0008-5472.CAN- specific, and even pathognomonic for tumor types and represent precious tools for diagnosis and relevant therapeutic targets (7, 8) . Although well described in humans, such translocations in dogs have only been explored and identified by fluorescence in situ hybridization (FISH) to date, in two canine hematological tumors: a chronic lymphocytic leukemia with a BCR-ABL fusion and a Burkitt's lymphoma with a IGH-MYC translocation (9) .
In the present study, we aim to demonstrate that pet dogs are relevant spontaneous models for human oncology with conserved key gene fusions, not restricted to hematological disorders by identifying chimeric transcripts with new and highly resolutive methods (NGS). Thus, we used whole transcriptome sequencing (RNA-Seq) of cancers with different origins to allow the detection of gene fusions without preconceived candidates. We report here, for the first time, chimeric transcripts in canine cancers reflecting chromosomal translocations that are comparable to human translocations in: a dermatofibrosarcoma protuberans-like (DFSP-like); an oligodendroglioma; and a diffuse large B-cell lymphoma (DLBCL). We then validated these gene fusions on DNA and RNA from the tumors, providing the breakpoint positions at the single-nucleotide resolution. We finally showed that similarly to the orthologous human cancers, these canine cancers not only share identical breakpoints but also overexpression of the targeted oncogenes. These striking molecular similarities between human and canine cancers pave the way for the use of the canine model in targeted therapies for the benefit of both human and dog patients.
Material & Method

Samples
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 7, 2017; DOI: 10.1158/0008-5472.CAN- Blood and tissue biopsy samples from dogs were collected by a network of veterinarians through the Cani-DNA biobank (http://dog-genetics.genouest.org), which is part of the CRB-Anim infrastructure. The work with dog samples was approved by the CNRS ethical board, France (35-238-13) for UMR6290 and dog owners consented to the use of data for research purposes anonymously. We selected 3 distinct cancers (lymphomas, sarcomas and gliomas) representing different tissues (neurological, subcutis, hematological) and different embryonic origins, with known fusions in the human counterpart. The set of samples included 3 lymphomas (2 DLBCLs and 1 T lymphoma), 2 gliomas and 1 dermatofibrosarcoma protuberans-like.
Histological diagnosis
The diagnosis of the six tumors was re-evaluated by dedicated veterinary (JA) and human pathologists (JMC and AR for the DFSP-like and the glioma respectively). 
DNA and RNA isolation
The germline DNA from blood, DNA and RNA from tissues were isolated using respectively the Blood L, Tissue and RNA II NucleoSpin® kits (Macherey-Nagel, Duren, Germany) according to the manufacturer's instructions. 
Identification of fusion transcripts
Candidate gene fusion transcripts were identified with CRAC and chimCT softwares (http://cractools.gforge.inria.fr/) using the CanFam3 canine genome reference. Fusion transcripts were manually filtered by discarding transcripts with less than five reads spanning the fusion junction and three reads encompassing the two fusion transcripts, as well as transcripts involving paralogous genes or pseudogenes, transcripts identified as read-through, transcripts with no Ensembl annotation ( Supplementary Table 1 ).
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RT-PCR
Reverse transcription was performed on 1 μg of total RNA from tumor or healthy tissue using the High-capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions.
Validation of the fused transcript
PCR amplifications were performed on cDNA samples diluted 1:40 using the Type-it Microsatellite PCR kit (Qiagen, Hilden, Germany) with dedicated primers (Supplementary Table 2 ). PCR products were sequenced with a 370 ABI sequencer using the BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA).
The presence of fusion transcripts was assessed by alignment of sequences on the CanFam 3 reference dog sequence (https://genome.ucsc.edu/).
Breakpoint mapping on genomic DNA
PCR amplifications were performed on DNA to validate fusion transcripts. Primers specific for each breakpoint (Supplementary Table 2 
Statistics
All statistical tests were performed with the R software.
Results and discussion
Author Manuscript Published OnlineFirst on September 7, 2017; DOI: 10.1158/0008-5472.CAN- Previous cytogenetic studies have underlined the importance of gene fusions in hematological disorders and sarcoma in humans (8) . To investigate gene fusions in canine cancers, we analyzed 6 tumors belonging to 3 distinct cancers, representing different tissues (neurological, subcutis, hematological) and embryonic origins, and for which the human corresponding tumors are known to involve key gene fusions. We performed RNA-Seq, using dedicated softwares followed by classical filters and manual curation to exclude false-positive chimeras, we finally identified 3 gene fusions in 3 of the 6 tumors (Table 1 and Supplementary Table 1 ).
1-A COL3A1-PDGFB fusion in a canine dermatofibrosarcoma protuberans-like
In human dermatofibrosarcoma protuberans (DFSP), the translocation t(17;22) leading to the fusion of the Collagen type 1 alpha 1 (COL1A1) and Platelet-derived growth factor B chain (PDGFB) genes is considered as pathognomonic of DFSP (10) . Thus, we analyzed a canine DFSP-like case ( Supplementary Figure 1 ) and we found a chimeric transcript resulting from the fusion between the Collagen type 3 alpha 1 (COL3A1) and the PDGFB genes. Since COL3A1 and COL1A1 are paralogous genes, we anticipated that this canine translocation is similar to the human one. Indeed, as in humans, the breakpoint in PDGFB is localized in intron 1 (Figure 1a ), moreover the fusion validation on the cDNA and the genomic DNA of this tumor (Figure 1b-d) shows a conserved reading frame between the first COL3A1 exons and the exon 2 of PDGFB. Similar to the situation in human DFSP (11), we hypothesized that this translocation, placing PDGFB under the regulation of the COL3A1 promoter, induces the overexpression of PDGFB in the canine DFSP-like tumor. This is confirmed by the expression levels of exons retained in the Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 7, 2017; DOI: 10.1158/0008-5472.CAN- chimeric transcript, which are increased on average 9.6-fold in comparison to healthy tissues (p-value <0.001, one-tailed Wilcoxon test) (Figure 1e ). Moreover, PDGFB protein is detectable in the tumor by immunostaining (Supplementary Figure 1) .
Complementary to this, the alignment of canine and human PDGFB protein sequences ( Supplementary Figure 2) shows the conservation of the 2 proteolytic cleavage sites in the canine PDGFB and in the putative chimeric protein resulting from COL3A1/PDGFB fusion. Under these conditions, the canine COL3A1/PDGFB should produce a chimeric precursor protein, transformed into a mature growth factor after proteolysis and forming an autocrine loop, as for the human COL1A1/PDGFB fusion (11) . Since the chimeric protein COL1A1/PDGFB is targeted by imatinib for human DFSP (7, 10) , regarding the genetic and biological similarities between human DFSP and canine DFSPlike, we predict similarities in treatment responses. Finally, we propose the COL3A1 gene as a new candidate partner gene for human DFSP, like the recently discovered COL1A2 (12).
2-A MBP-BRAF fusion in a canine glioma
Human gliomas are a heterogeneous group of tumors of the central nervous system with BRAF alterations (somatic mutations or fusions) described almost in all subgroups (13) .
Therefore we analyzed two canine grade 3 anaplastic oligodendrogliomas (WHO classification) ( Supplementary Figure 3) . In one of them, we identified a relevant chimeric transcript resulting from the fusion between the Myelin Basic Protein (MBP) and the B-Raf proto-oncogene (BRAF) genes. Like in human gliomas with breakpoints localized between BRAF intron 8 and 10 (14) , the breakpoint of BRAF in this canine glioma is within intron 7, orthologous to human BRAF intron 8 (Figure 2a ). This fusion Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
was validated on the cDNA and the genomic DNA of this tumor (Figure 2b-d) . The reading frame is conserved between the first MBP exons and the last exons of BRAF.
Since the MBP promoter is strongly active in glioma cells (15) , we anticipated that this translocation could also induce BRAF overexpression. We confirmed this hypothesis by measuring the expression levels of exons retained in the chimeric transcript; there was an average 12.8-fold increase in comparison to healthy tissues (p-value = 0.0039, onetailed Wilcoxon test) ( Figure 2E ). Moreover, BRAF protein is detectable in the tumor by immunostainning and a fused protein is detectable in the tumor sample by western blot ( Supplementary Figure 3) . Since the alignments of the canine and human BRAF protein sequences showed that the canine chimeric protein has lost its N-terminal autoinhibitory domain ( Supplementary Figure 4) , this alteration should induce a constitutive BRAF kinase activity as shown in human cancers (16) . In human gliomas, BRAF is mainly fused with KIAA1549 but other partners have been described (14) , while most of these fusions are found in astrocytomas, they are also reported in oligodendrogliomas (17) .
We propose MBP as a new candidate partner for BRAF fusions in human gliomas. For these human tumors, with limited therapeutic options, BRAF alterations offer new therapeutic strategies and clinical trials are ongoing (16) . In this context, spontaneous canine glioma with BRAF fusions provides a unique model to develop new and more efficient treatments.
3-An IGK-CCND3 fusion in a canine B-cell lymphoma
In human lymphomas, alterations during the natural recombination process of immunoglobulin genes lead commonly to fusions with oncogenes associated with their overexpression. Thus we analyzed 3 canine lymphomas (two DLBCLs, and one T-cell Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 7, 2017; DOI: 10.1158/0008-5472. CAN-16-2691 lymphoma) and found one aberrant transcript revealing a fusion between the Immunoglobulin light chain kappa locus (IGK) with Cyclin-D3 (CCND3) in one DLBCL sample (Table 1 ) (Figure 3a ). This fusion was validated on the cDNA and the genomic DNA of this tumor (Figure 3b-d) . Such translocations involving CCND3 and immunoglobulin genes have already been described in human B-cell malignancies including DLBCL, which could explain the overexpression of CCND3 found in 10% of human DLBCL (18) . Thus, we anticipated that the canine translocation also induces the overexpression of CCND3. This is supported by the fact that CCND3 is overexpressed in canine DLBCL (Figure 3e ) and the CCND3 protein is easily detectable by immunohistochemistry in the canine DLBCL (Supplementary Figure 5) . While, IGK-CCND3 fusion was not identified in human lymphomas, overexpression of CCND3 driven by IG-mediated translocations are expected and searched in cases showing break-apart probes for CCND3. Moreover fusions involving IGK and other cyclins, of which CCND2, have already been detected (19) . In addition, the overexpression of CCND3 in human DLBCL is a prognostic factor associated with poor clinical outcome (20) . Thus, canine lymphomas with fusions involving cyclin D could be used for clinical trials targeting cyclins.
Conclusion
Our work reveals similar fusions in corresponding cancers between dogs and humans and identifies for the first time chimeric transcripts involving the same fused oncogenes with similar rearrangements leading to malignancy. The identification of these three fused transcripts in three different tumors supports the existence of other fused transcripts in other subtypes of canine cancers, similar to what is found in humans. With Author Manuscript Published OnlineFirst on September 7, 2017; DOI: 10.1158/0008-5472.CAN- comparison to exons localized in 5' of the breakpoint (** p-value ≤ 0.01, two-tailed paired two-Sample t-test). Expression levels of exons 7-8, flanking the breakpoint, showed that the BRAF wild type transcript is significantly under-expressed in the tumor (p-value ≤ 0.01, one-tailed Wilcoxon test). These results showed that the overexpression of BRAF exons retained in the chimeric transcript is linked to the fusion. 
